Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine

Lipids in Health and Disease

Volumn 2, Issue , 2003, Pages 1-6

  De Gómez Dumm, Nelva T ^a   Giammona, Ana M ^c   Touceda, Luis A ^b  

^a INSTITUTO DE INVESTIGACIONES BIOQUÍMICAS DE LA PLATA INIBIOLP   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PHOSPHOLIPID; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; AMINO ACID BLOOD LEVEL; ANISOTROPY; ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE FLUIDITY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; ERYTHROCYTE LEVEL; ERYTHROCYTE MEMBRANE; FEMALE; FLUORESCENCE ANALYSIS; HEMODIALYSIS; HUMAN; HUMAN CELL; MALE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 3042685021     PISSN: 1476511X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-511X-2-1     Document Type: Article

References (36)

1. Zoccali C: Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant 2000, 15:454-457.
2. Green D, Stone NJ and Krumlowsky A: Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovascular Dis 1983, 26:133-144.
3. Jeppesen J, Hein JO, Suadicani P and Gyntelberg F: Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen male study. Circulation 1998, 97:1029-1036.
4. Assman G and Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol 1992, 70:733-737.
5. Hokanson JE and Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascular Risk 1996, 3:213-219.
6. Gómez Dumm INT de, Giammona AM, Touceda LA and Raimondi C: Lipid abnormalities in chronic renal failure patients undergoing hemodialysis. Medicina 2001, 61:142-146.
7. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L and Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioescler Throm Vasc Biol 1997, 11:2554-2558.
8. Hankey GJ and Eikelboom JW: Homocysteine and vascular disease. Lancet 1999, 354:407-413.
9. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer E, El Selhub J, Kutner M and Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentration. Circulation 1996, 94:2742-2748.
10. Dennis VW and Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996, 57 Suppl:S11-S17.
11. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D and Andria G et al.: Plasma homocysteine as a risk factor for vascular disease. JAMA 1997, 277:1775-1781.
12. Mallamaci I, Zoccali C, Tripeti G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS and Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney International 2002, 61:609-614.
13. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH and Willett WC: Homocysteine metabolism and risk of myocardial infarction - relation with vitamin B-6, vitamin B-12, and folate. Am J Epidemiol 1996, 143:845-859.
14. Henning BF, Riezler R, Tepel M, Langer K, Raidt H, Graefe U and Zidek W: Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 1999, 83:314-322.
15. Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Ouimet D and Leblanc M: Hyperhomocysteinemia in hemodialysis patients: effects of 12 month supplementation with hydrosoluble vitamins. Kidney Int 2000, 58:851-858.
16. Bostom AG, Shemin D and Lapane KL: Hyperhomocysteinemia and traditional cardiovasculardisease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995, 114:93-103.
17. Gómez Dumm NT de, Giammona AM and Touceda L: Variations in the lipid profile of patients with chronic renal failure, treated with folic acid. Int J Vitam Nutr Res 2003, 73:215-220.
18. Touceda LA, Arroyo D, Giammona AM, Onofri MF, Iglesias O, Bruseghini S, Bruzzo L and Ruiz de la Fuente ME: Efecto de mega-dosis intravenosas de ácido fólico sobre la homocisteína en pacientes en hemodiálisis. Rev Nefrol Dial y Traspl 2001, 55:21-28.
19. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Shelhub J and Rosenberg I: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996, 49:147-152.
20. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A and Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentration in dialysis patients. Clin Nephrol 1993, 40:236-240.
21. Chaveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P and Jungers P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996, 22:106-109.
22. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drüeke T and Massy ZA: Effective correction of hyperhomocyst(e)inemia in hemodialysis patients by i.v. folinic acid and piridoxine therapy. Kidney Int 1999, 56:2292-2296.
23. McKinley MC, McNulty H, McPartlin J, Strain JJ, Pentieva K, Ward M, Weir DG and Scott JM: Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 2001, 73:759-764.
24. Frantzen F, Faaren AL, Alfheim I and Nordhei AK: Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998, 44:311-316.
25. Kaysen GA: Hyperlipidemia of chronic renal failure. Blood Purif 1994, 12:60-67.
26. Peck LW, Monsen ER and Ahmad S: Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am J Clin Nut 1996, 64:210-214.
27. Dasgupta A, Kenny MA and Ahmad S: Abnormal fatty acid profile in chronic hemodialysis patients: possibly deficiency of essential fatty acids. Clin Physiol Biochem 1990, 8:238-243.
28. Koorts AM, Viljoen M and Kruger MC: Red blood cell fatty acid profile in chronic renal failure patients receiving maintenance haemodialysis treatment. Prostaglandins Leukot Essent Fatty Acids 2002, 67:13-18.
29. Siguel E: A new relationship between total/high density lipoprotein cholesterol and polyunsaturated fatty acids. Lipids 1996, 31:S51-S56.
30. Siguel EN and Lerman RH: Fatty acid patterns in patients with angiographically documented coronary artery disease. Metabolism 1994, 43:982-993.
31. Sinclair H: Dietary fats and coronary heart disease. Controversy. Lancet 1980, i:414-415.
32. Kingsbury KJ, Brett C, Stovold R, Chapman A, Anderson J and Morgan DM: Abnormal fatty acid composition and human atherosclerosis. Postgrad Med J 1974, 285:425-440.
33. Kingsbury KJ: Polyunsaturated fatty acids and myocardial infraction. Lancet 1970, i:648-676.
34. Berlin E, Bathena SJ, Judd JHT, Nair PP, Jones DY and Taylor PR: Dietary fat and hormone effects on erythrocyte membrane fluidity and lipid composition in adult women. Metabolism 1989, 38:790-796.
35. Stubbs CD and Smith AS: The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984, 779:89-137.
36. Garda HA and Brenner RR: Short-chain aliphatic alcohols increase rat liver microsomal membrane fluidity and affect the activities of some microsomal membrane-bound enzymes. Biochim Biophys Acta 1984, 769:160-170.